TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00

Key Points

• B. Riley has increased the target price for TG Therapeutics (NASDAQ:TGTX) from $53 to $55, indicating a potential upside of 70.58% from its previous close, while maintaining a "buy" rating.
• Goldman Sachs recently upgraded TG Therapeutics to a "hold" rating with a target price set at $37.00, contributing to a consensus rating of "Moderate Buy" among analysts.
• Despite a quarterly earnings miss, TG Therapeutics reported a 92.1% year-over-year revenue increase, posting $141.15 million in revenue for the quarter.

TG Therapeutics (NASDAQ:TGTX - Free Report) had its price target increased by B. Riley from $53.00 to $55.00 in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a buy rating on the biopharmaceutical company's stock. B. Riley also issued estimates for TG Therapeutics' Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.33 EPS, FY2025 earnings at $0.84 EPS, FY2026 earnings at $1.74 EPS, FY2027 earnings at $2.13 EPS and FY2029 earnings at $4.44 EPS.

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $48.00.

TG Therapeutics Trading Down 0.7%

Shares of TGTX traded down $0.24 on Wednesday, reaching $32.37. 3,197,005 shares of the company's stock were exchanged, compared to its average volume of 2,006,223. TG Therapeutics has a 12 month low of $21.16 and a 12 month high of $46.48. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $5.14 billion, a P/E ratio of 87.49 and a beta of 1.88. The business has a 50 day moving average price of $31.91 and a two-hundred day moving average price of $35.65.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business's revenue was up 92.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 20,852 shares of the firm's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.64% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its holdings in shares of TG Therapeutics by 2.5% during the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company's stock worth $274,180,000 after acquiring an additional 184,339 shares during the last quarter. Geode Capital Management LLC lifted its position in TG Therapeutics by 6.3% during the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company's stock valued at $126,033,000 after purchasing an additional 207,890 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in TG Therapeutics by 21.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock valued at $75,683,000 after buying an additional 345,059 shares in the last quarter. Hood River Capital Management LLC grew its position in shares of TG Therapeutics by 0.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company's stock worth $56,415,000 after buying an additional 11,018 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of TG Therapeutics by 1,809.9% in the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company's stock valued at $47,830,000 after acquiring an additional 1,149,526 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.